Prospective Research was founded with a vision to develop novel, lifesaving antibiotics.
Founders Adam Hill (CEO), Jake Cotter (COO) and Dakota Hamill (CSO) are using Life Science Consortium of the North Shore facilities at Endicott College for their biological work and the analytical equipment available at NSIV headquarters to help characterize their new antibiotics.
There has not been a new class of antibiotic brought to market in over 30 years. Bacterial resistance to the current classes of antibiotics is growing at an alarming rate. It is estimated that antibiotic resistant infections will surpass cancer as the world’s leading cause of death by 2050.
Soil microbes are the most prolific producers of antibiotics, yet only 10% of their potential has been accessed. When soil microbes are cultured in the lab, they are removed from the natural stimuli that are essential for antibiotic production. The result is that life-saving antibiotics, with massive market potential, have gone undiscovered.
Prospective Research proprietary StimKey™ technology restores the essential stimuli necessary for antibiotic production, gaining exclusive access to novel chemical scaffolds.
The Salem News ran a feature on Prospective Research in July detailing their founding story.